FARMAK PHARMACEUTICALS UK LTD
Get an alert when FARMAK PHARMACEUTICALS UK LTD files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Next accounts due
2026-12-31 (in 7mo)
Last filed for 2025-03-31
Confirmation statement due
2027-02-16 (in 9mo)
Last made up 2026-02-02
Watchouts
None on the register
Cash
£54K
Latest balance sheet
Net assets
-£4M
Equity attributable
Employees
15
Average over period
Profit before tax
-£4M
Period ending 2025-03-31
Net assets
1-year trend · vs Consumer Discretionary median
Accounts
1-year trend · latest reflected 2025-03-31
| Metric | Trend | 2025-03-31 |
|---|---|---|
| Turnover | £342,733 | |
| Operating profit | -£3,514,576 | |
| Profit before tax | -£3,632,134 | |
| Net profit | -£3,632,134 | |
| Cash | £53,658 | |
| Total assets less current liabilities | £960,082 | |
| Net assets | -£3,641,532 | |
| Equity | -£3,641,532 | |
| Average employees | 15 | |
| Wages | £1,055,830 |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2025-03-31 |
|---|---|---|
| Operating margin | -1025.5% | |
| Net margin | -1059.8% | |
| Return on capital employed | -366.1% | |
| Current ratio | 0.28x | |
| Interest cover | -29.90x |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Audit & accounting basis
- Accounting basis
- FRS 102 §1A
- Reporting scope
- Consolidated group
- Abridged
- Yes — abridged accounts (limited disclosure)
- Auditor
- Millet Audit Ltd
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.”
Group structure
- FARMAK PHARMACEUTICALS UK LTD · parent
- A&S Pharma Holdings Ltd 100%
- Cygnus Pharma Ltd 100%
- Ascenders Consulting Services Limited 100%
- Euro-Link Pharma Ltd 100%
Significant events
- “On 19th September 2025, the company acquired 100% of A&S Pharma Holdings Ltd, Cygnus Pharma Ltd, Ascenders Consulting Services Limited and Euro-Link Pharma Ltd. The acquisition was accounted for using the acquisition method. The consideration was £1,594,019 in cash.”
- “As part of the Group's international expansion strategy, Farmak Pharmaceuticals UK Ltd will take on the subsidiaries trade and assets throughout 2026 namely being A&S Pharma Holdings Ltd, Cygnus Pharma Ltd, Euro-Link Pharma Ltd, and Ascenders Consulting Services Limited, these will in turn be ceasing their current operations.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
1 active · 0 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| HOURIGAN, Marc Anthony | Director | 2024-01-09 | Mar 1970 | Irish |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Farmak Ag | Corporate entity | Shares 50–75%, Voting 50–75%, Appoints directors | 2024-01-22 | Active |
| Filya Zhebrovska | Individual | Significant influence | 2024-01-22 | Active |
| Marc Anthony Hourigan | Individual | Shares 25–50%, Voting 25–50%, Appoints directors | 2024-01-22 | Active |
| Mr Mark Anthony Hourigan | Individual | Shares 75–100%, Voting 75–100%, Appoints directors | 2024-01-09 | Ceased 2024-01-22 |
Filing timeline
Last 15 of 15 total filings
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2026-02-12 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2026-02-06 | AA | accounts | Accounts with accounts type group | |
| 2025-09-25 | PSC01 | persons-with-significant-control | Notification of a person with significant control | |
| 2025-09-24 | PSC04 | persons-with-significant-control | Change to a person with significant control | |
| 2025-07-31 | AA01 | accounts | Change account reference date company previous extended | |
| 2025-06-27 | PSC01 | persons-with-significant-control | Notification of a person with significant control | |
| 2025-02-04 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2024-05-13 | AD01 | address | Change registered office address company with date old address new address | |
| 2024-03-06 | AD01 | address | Change registered office address company with date old address new address | |
| 2024-02-02 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2024-02-02 | PSC02 | persons-with-significant-control | Notification of a person with significant control | |
| 2024-02-02 | CH01 | officers | Change person director company with change date | |
| 2024-02-02 | PSC07 | persons-with-significant-control | Cessation of a person with significant control | |
| 2024-02-02 | SH01 | capital | Capital allotment shares | |
| 2024-01-09 | NEWINC | incorporation | Incorporation company |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 6
- Capital events
- 0
- Officers appointed
- 0
- Officers resigned
- 0
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.
Year-on-year
Latest filed period vs the prior one